Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 14/20 | 1.00 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13093321 | 0.90 | P2RY1 (0.81) | P2RY1STING1EPHX2IGF1RNPC1 | |
| SCHEMBL2880366 | 0.90 | P2RY1 (0.81) | P2RY1STING1EPHX2IGF1RNPC1 | |
| SCHEMBL2873026 | 0.89 | P2RY1 (0.80) | P2RY1STING1EPHX2IGF1RNPC1 | |
| SCHEMBL2875384 | 0.89 | P2RY1 (0.80) | P2RY1STING1EPHX2IGF1RNPC1 | |
| SCHEMBL2873021 | 0.89 | P2RY1 (0.80) | P2RY1STING1EPHX2IGF1R | |
| SCHEMBL2877891 | 0.87 | P2RY1 (0.77) | P2RY1STING1EPHX2IGF1RP2RY14 | |
| SCHEMBL2872744 | 0.85 | P2RY1 (1.00) | P2RY1STING1EPHX2IGF1RNPC1 | |
| SCHEMBL2875413 | 0.84 | P2RY1 (0.71) | P2RY1EPHX2NPC1RAB9AMEN1 | |
| SCHEMBL13437657 | 0.83 | P2RY1 (0.71) | P2RY1NPC1RAB9AMEN1MAPT | |
| SCHEMBL2880008 | 0.82 | P2RY1 (0.69) | P2RY1STING1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | claimed |
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1899299-B1 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1899299-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002635-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002635-A2 | C-LINKED CYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293336-A1 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY11, P2RY1, P2RY13 | P2RY1 2/4885STING1 1302/4885EPHX2 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.